BR100 Decreased By (-0.17%)
BR30 Decreased By (-0.69%)
KSE100 Decreased By (-0.06%)
KSE30 Decreased By (-0.38%)
AGHA 6.06 Increased By ▲ 0.01 (0.17%)
BECO 3.89 Increased By ▲ 0.06 (1.57%)
BML 57.01 Decreased By ▼ -1.32 (-2.26%)
BOP 28.30 Decreased By ▼ -0.05 (-0.18%)
CNERGY 12.35 Decreased By ▼ -1.29 (-9.46%)
CSIL 5.29 Increased By ▲ 0.08 (1.54%)
FCCL 52.55 Increased By ▲ 0.27 (0.52%)
FFL 12.90 No Change ▼ 0.00 (0%)
FNEL 1.13 No Change ▼ 0.00 (0%)
KEL 5.85 Increased By ▲ 0.06 (1.04%)
KOSM 5.60 Increased By ▲ 0.09 (1.63%)
LOTCHEM 23.90 Increased By ▲ 0.01 (0.04%)
MLCF 91.51 Increased By ▲ 1.00 (1.1%)
NBP 158.00 Decreased By ▼ -1.72 (-1.08%)
NCPL 49.45 Decreased By ▼ -0.15 (-0.3%)
NPL 51.95 Increased By ▲ 0.15 (0.29%)
OGDC 307.00 Increased By ▲ 0.22 (0.07%)
PACE 9.29 Increased By ▲ 0.14 (1.53%)
PAEL 32.30 Decreased By ▼ -0.03 (-0.09%)
PIBTL 12.93 No Change ▼ 0.00 (0%)
PPL 214.00 Increased By ▲ 0.07 (0.03%)
PRL 87.26 Decreased By ▼ -9.70 (-10%)
PTC 45.51 Increased By ▲ 0.32 (0.71%)
SSGC 22.29 Decreased By ▼ -0.24 (-1.07%)
TBL 9.15 Increased By ▲ 0.13 (1.44%)
TELE 6.60 Decreased By ▼ -0.12 (-1.79%)
TPL 26.00 Increased By ▲ 0.09 (0.35%)
TPLP 12.80 Increased By ▲ 0.20 (1.59%)
TREET 23.70 Increased By ▲ 0.24 (1.02%)
TRG 51.70 Decreased By ▼ -0.26 (-0.5%)
World

COVID-19 vaccine patent waiver is ‘no silver bullet’: EU's Michel

  • "The question of intellectual property rights will likely be raised," Michel told a news conference ahead of the summit starting on Friday.
Published Updated
By

BRUSSELS: A proposed waiver of intellectual property rights for COVID-19 vaccines and treatments is "no silver bullet", European Council president Charles Michel said on Thursday, adding he expected the topic to feature at the G7 summit.

"The question of intellectual property rights will likely be raised," Michel told a news conference ahead of the summit starting on Friday.

"The patent waiver might sound good, but it's no silver bullet. The TRIPS agreement already offers flexibility and we want to focus on concrete proposals, such as promoting voluntary licences and knowledge transfers and patent-pooling on mutually agreed terms," he continued.

Comments

Comments are closed for this article.